U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patien
Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo
ANDEMBRY approval expands CSL's HAE franchise and underscores the company's legacy of delivering transformational innovations to the HAE community for over four decades
KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) approved ANDEMBRY® (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. By targeting factor XIIa, a plasma protein that plays a key role in attacks of swelling in people with HAE, ANDEMBRY inhibits the top of the HAE cascade to prevent HAE attacks. ANDEMBRY, the only treatment to offer once-monthly dosing from the start for all patients, is a subcutaneous self-injection delivered in 15 seconds or less via an autoinjector with a citrate-free formula.
HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. HAE occurs in about 1 in 50,000 people of any ethnic group.
'ANDEMBRY, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method,' said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. 'ANDEMBRY underscores our long-standing and enduring commitment to better the lives of the patients we serve, including those suffering with HAE. I'd like to thank all the physicians, patients and my colleagues who contributed to this exciting milestone for HAE patients and CSL.'
The approval is supported by data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY:
Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period.
Reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo.
Achieved more than 99 percent median reduction and an 88 percent mean reduction in HAE attacks requiring on-demand therapy, compared to placebo.
Attained more than 99 percent median reduction and a 90 percent mean reduction in moderate or severe attacks, compared to placebo.
The most common adverse reactions in the pivotal trial (incidence ≥7%) are nasopharyngitis and abdominal pain.
A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. In the pivotal trial and the open-label extension study, injection-site reactions (e.g., injection-site bruising, injection-site erythema, injection-site hematoma, injection-site pruritus, injection-site urticaria) were reported in 23 (14%) patients.
'We've made significant progress in treating hereditary angioedema, yet many patients still experience painful and sometimes life-threatening HAE attacks and require frequent injections to manage them,' said Dr. Tim Craig, Professor of Medicine, Pediatrics and Biomedical Sciences at Penn State University. 'We now have a new option to manage this condition through a new target, as it allows us for the first time to inhibit the top of the HAE cascade by targeting factor XIIa.'
'ANDEMBRY, a novel once-monthly subcutaneous treatment that inhibits factor XIIa, is a welcome addition to the HAE treatment landscape,' said Anthony J. Castaldo, CEO and Chairman of the Board, US HAE Association and HAE International. 'People with HAE now have another choice for lessening the burden associated with this lifelong condition and realizing the community's shared goal of experiencing life to the fullest.'
This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdon (UK), the European Union (EU), Japan, Switzerland, and United Arab Emirates.
CSL Behring will launch ANDEMBRY commercially immediately, with availability before the end of June. Healthcare professionals and patients interested in learning more about ANDEMBRY or accessing the therapy are encouraged to utilize ANDEMBRY ConnectSM, designed to offer comprehensive support and assistance through various programs. For more information, call 844-423-4273 or visit www.ANDEMBRY.com.
About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death.
About ANDEMBRYANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a new type of once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain FDA approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators.
About the VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, an investigational first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing.
The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks.
IMPORTANT SAFETY INFORMATION
What is ANDEMBRY?ANDEMBRY® (garadacimab-gxii) injection, for subcutaneous use, is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in people 12 years and older.
It is not known if ANDEMBRY is safe and effective in children under 12 years of age.
What should I tell my healthcare provider before using ANDEMBRY?Before using ANDEMBRY, tell your healthcare provider about any medical condition you may have, especially if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if ANDEMBRY can harm your unborn baby or if ANDEMBRY passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while using ANDEMBRY.
Tell your healthcare provider about all medications you take, including prescription medicines, over-the-counter treatments, vitamins, and herbal supplements.
How should I use ANDEMBRY? Use ANDEMBRY exactly as instructed by your healthcare provider. Detailed instructions for use can be found in the patient information section of the full prescribing information.
ANDEMBRY is given as an injection under your skin (subcutaneous) by you or a caregiver. Your healthcare provider should show you or your caregiver how to prepare and inject your dose of ANDEMBRY before you inject yourself for the first time. Do not try to inject ANDEMBRY unless you have been trained by your healthcare provider.
What are the possible side effects of ANDEMBRY?The most common side effects of ANDEMBRY include:
Redness, itchiness, and bruising (injection-site reactions)
Stomach (abdominal) pain
Runny or stuffy nose, sneezing, watery eyes (nasopharyngitis)
Please see full prescribing information for ANDEMBRY, including patient information and instructions for use.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.
About CSLCSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
For more information about CSL, visit www.CSL.com.
Media ContactsValerie BombergerCSLOffice: +1 610-291-5388 Mobile: +1 267-280-3829 Email: valerie.bomberger@cslbehring.com
Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: etanjalie.ayala@cslbehring.com
Greg HealyCSLMobile: +1 610-906-4564Email: greg.healy@cslbehring.com
In Australia: Kim O'DonohueCSLMobile: +61 449 884 603Email: kim.odonohue@csl.com.au
Brett FoleyCSLMobile: +61 461 464 708 Email: brett.foley@csl.com.au
Investors ContactChris CooperCSLMobile: +61 455 022 740Email: chris.cooper@csl.com.au
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Mark Parkinson, Zimmet Healthcare Launch Park Place, a Groundbreaking New Platform to Support Long-Term Care Providers, Moving Skilled Nursing Forward, Together
UNCASVILLE, Conn., Aug. 13, 2025 /PRNewswire/ — Park Place is a website designed to help long-term care providers succeed both clinically and financially. Launching today, the online, free platform led by CEO Mark Parkinson, the former longtime President & CEO of the American Health Care Association, and Zimmet Healthcare, leads providers and vendor partners in their pursuit of clinical and financial success. To achieve these goals, Park Place will deliver content by Parkinson, Marc Zimmet, CEO of Zimmet Healthcare Services Group, and a who's who of industry experts, one-of-its-kind analysis, and unique video and podcast streams on a weekly basis. The roster of accomplished contributors includes JJ Rabinowich, Glenn Van Ekeren, Anne Tumlinson, Steven Littlehale, with many more to come. 'We are so excited to present this new space for long-term care professionals to discover, learn, and lead. Park Place intends to elevate the conversations shaping our field – uniting insights, expertise, and forward-thinking content under one roof. Whether you're here to stay informed, stay ahead, or simply stay connected, you're in the right place,' Parkinson said. Park Place is hosted on zPAX – the Post-Acute eXchange, Zimmet Healthcare's technology platform. Omnicare, a CVS Health company, is the launch sponsor of Park Place. Park Place builds on the achievements of the book Parkinson co-authored last year: 'Long Term Care Success: How Senior Care Communities Thrive Clinically and Financially.' The Park Place launch took place at the annual Zimmet Conference at the Mohegan Sun resort, where thousands of long-term care stakeholders gathered. Marc Zimmet said Park Place will dig into the details of the long-term care business in fresh and innovative ways, utilizing Zimmet Healthcare's vast data resources and expertise. 'For skilled nursing facilities, reimbursement is broad and complex field that increasingly confounds the provider community. Park Place's mission to help operators improve quality is closely tied to reimbursement constraints, so we'll be taking deep dives into the different forces and factors that shape provider revenue,' Zimmet said. Park Place is home for all long-term care providers — skilled nursing, assisted living, and independent living — to visit if they want to learn about how operators are succeeding. The Park Place mission statement is simple: Our Mission Is Your Success. Access Park Place at and start discovering the exclusive insights, interactive tools, and expert commentary for operators, owners, clinicians, and decision-makers across the long-term care continuum. 'We are focused on what matters: operations, policy, financing, clinical care, innovation, and the interaction between them all. The content we provide is part of a larger effort to reframe how the industry sees itself and create a community destination for skilled nursing and long-term care leaders,' Parkinson said. For Media Inquiries: Contact PublicRelations@
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Whole Genome Sequencing Market to Reach New Heights by 2030
'With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving strong market growth at a projected CAGR of 15.1% over the next five years.' BOSTON, Aug. 13, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'Whole Genome Sequencing: Global Markets' is projected to grow from $3 billion in 2025 to $6.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2030. This report provides insights into the current and future market potential of whole genome sequencing (WGS), with global and regional projections through 2030. It includes market estimates by product and service type, covering instruments, consumables, and services. The workflow is segmented into pre-sequencing, sequencing, and data analysis. End users include research institutes, hospitals and clinics, pharmaceutical companies, and others. Applications span infectious diseases, cancer research, rare genetic diseases, and pharmacogenomics. The report also breaks down data by four regions: North America, Europe, Asia-Pacific, and the Rest of the World. This report is particularly relevant today because whole genome sequencing (WGS) is emerging as a powerful tool for diagnosing, treating, and monitoring conditions like cancer, rare inherited disorders, and neurological diseases. Its ability to provide comprehensive genomic information helps reduce reliance on single-gene tests or invasive procedures. WGS is also increasingly used in drug development to identify better disease targets and select suitable patients for clinical studies through genomic profiling. The factors driving the market's growth include: Research on Cancer Genomics and Rare Inherited Diseases: Whole genome sequencing is vital for identifying genetic mutations linked to cancer and rare diseases. It enables faster, more accurate diagnoses and helps researchers develop targeted treatments by understanding disease mechanisms at the genetic level. Falling Genome Sequencing Costs: Due to technological advances, the cost of sequencing a genome has dropped significantly, making it more accessible for clinical and research use. This affordability is expanding its adoption across the healthcare, biotech, and academic sectors. Focus on Targeted Therapies and Personalized Medicine: WGS supports personalized medicine by revealing genetic profiles that guide treatment decisions. It helps tailor therapies to individual patients, improves drug response, and enables early disease detection and prevention strategies. Request a sample copy of the global market for whole genome sequencing report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $2.6 billion Market size forecast $6.1 billion Growth rate CAGR of 15.1% from 2025 to 2030 Segments covered Product and Service Type, Workflow Type, Application, End User and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered The U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, India, South Korea, Australia, Rest of Europe, Rest of Asia-Pacific, South America, the Middle East and Africa Market drivers • Research on cancer genomics and rare inherited diseases. • Falling genome sequencing costs. • Focus on targeted therapies and personalized medicine. Interesting facts: The growing focus on personal genomics and prenatal testing drives the market's growth across all regions. WGS-based diagnostics lead to more precise diagnosis and enable personalized treatment for each patient. The report addresses the following questions: What are the projected size and growth rate of the market?– The global EGS market was valued at $2.6 billion in 2024 and is expected to reach $6.1 billion by the end of 2030 at a CAGR of 15.1%. Which factors are driving the growth of the market?– The increasing research on cancer genomics and rare inherited diseases and the growing focus on personalized medicine. What are the key challenges and opportunities of the market?– Data analysis challenges and lack of infrastructure in emerging markets will challenge market growth during the forecast period.– The growing role of whole genome sequencing (WGS) in drug development and the increasing government initiatives to promote it create market opportunities. Which market segments are covered in the report?– The market is segmented based on product and service type, workflow, application, end user and region. Product and service types include consumables, instruments, and services. Consumables are further segmented into library preparation kits, reagents and accessories.– Workflow sub-segments include pre-sequencing, sequencing, and data analysis. End users include research institutes, hospitals and clinics, and pharmaceutical companies. Applications include infectious diseases, cancer research, rare genetic diseases, and pharmacogenomics. The market is segmented by geographical region into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. Asia-Pacific includes China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the World (RoW) includes South America, the Middle East and Africa. It includes global revenue ($ Million) for the base year of 2024 and estimated data for the forecast period 2025 through 2030. Which product type will be dominant through 2030?– Consumables segment will dominate the market through the forecast period. Which region has the highest market share?– North America accounted for a 50.9% share of the market in 2024. Related reports: Global Microbiome Sequencing Market: The report analyzes the microbiome sequencing market, segmenting it by component, sequencing technology, laboratory type, application, and end user. It explores trends, market drivers, restraints, and opportunities, along with macroeconomic influences and regulatory developments. The study also highlights technological innovations, patent activity, ESG factors, and competitive dynamics, including profiles of leading companies. Regions covered include North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, providing a global perspective on market growth and challenges. Global DNA Sequencing: Research, Applied and Clinical Markets: This report presents an in-depth analysis of the DNA sequencing market, focusing on its status and future potential. It explores market drivers, restraints, and opportunities, along with competitive dynamics and product offerings. The market is segmented by technology (NGS, TGS, pyrosequencing, and Sanger sequencing), product and service types, end users, applications, and disease categories. It also includes company profiles with financials, product portfolios, and recent developments. Geographically, the report covers North America, Europe, Asia-Pacific, and the Rest of the World, offering a global perspective on market trends and forecasts. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo – View original content:
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential game changer that addresses both the pain of injections and the low efficiency of oral formulations In the obesity treatment market, delivery technology is expected to be the decisive factor shaping future leaders SEOUL, South Korea, Aug. 13, 2025 /PRNewswire/ — Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study. This was based on the healthy volunteer study using semaglutide microneedle patch using Daewoong Therapeutics' CLOPAM® (CLOsed Packed Aero-pressured Microneedle) drug-delivery platform. The study directly compared delivery efficiency with semaglutide subcutaneous injection. In the trial, 70 healthy adults received single dose of either a semaglutide microneedle patch or a subcutaneous injection. Plasma concentrations were measured and then compared with results from semaglutide subcutaneous injection under the same conditions. After adjusting to equivalent dose, the patch showed more than 80%relative bioavailability compared with injection. This result is the highest reported for a microneedle patch with the same active ingredient, far exceeding the approximately 30 percent achieved by existing patches. It also showed around 160 times higher bioavailability than semaglutide oral tablet. Therapeutic plasma levels were maintained for one week, supporting the potential for once-weekly dosing with a single high-load patch. The exposure profile was comparable to that of the injectable counterpart, which strengthens the commercial prospects for a patch-based obesity treatment. Technology as the Decisive Factor in the Obesity Market According to Grand View Research, the global obesity therapeutics market is valued at 15.9 billion US dollars in 2024 and is projected to grow to 60.5 billion US dollars by 2030. Currently, therapeutic and safety advantages in the GLP-1 drug class are limited, and experts expect Experts expect delivery technologies improving both bioavailability and patient convenience will be the factor that determines future market leaders. Microneedle patches are attracting attention because they address two key limitations of current therapies: pain of injections and low drug delivery efficiency of oral formulations. While semaglutide oral tablet is available on the market, it has very low bioavailability and requires complex medication regimen, such as fasting before dosing, limiting water intake, and avoiding co-administration with other drugs for chronic patients potentially lowering adherence. A once-weekly microneedle patch offers a simpler, needle-free option that could be used by a wider range of patients, including those who avoid injections. Daewoong's Microneedle Technology Innovation Leading the Global Market The results were made possible by Daewoong Therapeutics' patented CLOPAM® microneedle platform technology, a dissolving-type microneedle technology designed for precise, skin-based drug delivery. The platform uses pressurized drying and hermetic packaging to improve drug uniformity and stability, allowing accurate dosing with minimal contamination risk. CLOPAM® currently has 52 patent filings worldwide and is positioning to be one of Daewoong's leading technologies. Unlike other injectable products containing semaglutide that require cold-chain storage, Daewoong's patches remain stable at room temperature, which can reduce distribution costs. They also help cut down on medical waste from syringes and needles, aligning with sustainability goals in healthcare. Based on these results, Daewoong Therapeutics is planning to broaden the collaborative initiatives to the global market via technology licensing, co-development, and out-licensing to prepare for commercialization. 'The microneedle patch must achieve not only high bioavailability but also a drug load sufficient for therapeutic effect,' said Bok-Ki Kang, CEO of Daewoong Therapeutics. 'In this study, we incorporated a high dose of semaglutide into a single patch and showed the potential for once-weekly application. This overcomes a key limitation of previous microneedle approaches and provides a strong foundation for global technology transfer and commercialization.' 'Microneedle formats have long promised better adherence, but high-dose delivery has been a challenge,' said Seong-Soo Park, CEO of Daewoong Pharmaceutical. 'This work is the first to overcome that barrier. We plan to expand microneedle technology to a wide range of biologics to lead the global platform market.' About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company headquartered in South Korea. The company develops, manufactures, and markets innovative medicines and healthcare solutions with the mission to improve quality of life worldwide. Daewoong specializes in treatments for intractable and rare diseases, supported by in-house research and development, open innovation, and advanced manufacturing capabilities. Recent achievements include the development and approval of novel drugs for gastroesophageal reflux disease (Fexuprazan) and Type 2 diabetes (Enavogliflozin) in consecutive years. The company is also developing a first-in-class oral anti-fibrotic agent for idiopathic pulmonary fibrosis (Bersiporocin), which has received both orphan drug designation and Fast Track status from the US FDA. About Daewoong Therapeutics Daewoong Therapeutics Inc., is a subsidiary of Daewoong Group located in South Korea. The company is focused on developing novel drug delivery systems including the dissolving microneedle platform, CLOPAM®. CLOPAM® is currently being applied to various fields including obesity/metabolic diseases and others with aims to improve patient convenience and medication adherence.
